Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yan Tu

Showing results (301-310 of 321) with videos related to

Pageof 33
Sort By:
Frontiers in Immunology|October 20, 2022
PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinomaYu-Min Zhong, Kai Yin, Yu Chen, et al.
Signal Transduction and Targeted Therapy|December 6, 2023
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II studySi-Yang Liu, Song Dong, Xue-Ning Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2017
Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor CellsBen-Yuan Jiang, Yang-Si Li, Wei-Bang Guo, et al.
Journal of Translational Medicine|April 2, 2024
Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancerWei-Chi Luo, Shi-Qi Mei, Zi-Jian Huang, et al.
Journal of Hematology & Oncology|April 17, 2020
Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter studyChang Lu, Xiao-Rong Dong, Jun Zhao, et al.
Cancer Discovery|May 11, 2022
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung CancerJia-Tao Zhang, Si-Yang Liu, Wei Gao, et al.
Lung Cancer (Amsterdam, Netherlands)|November 28, 2017
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancerHai-Yan Tu, E-E Ke, Jin-Ji Yang, et al.
Lung Cancer (Amsterdam, Netherlands)|January 30, 2022
Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancerJianhua Chang, Yi-Long Wu, Shun Lu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 19, 2023
Allelic Context of EGFR C797X-Mutant Lung Cancer Defines Four Subtypes With Heterogeneous Genomic Landscape and Distinct Clinical OutcomesChang Lu, Xue-Wu Wei, Zhen Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 10, 2025
First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled TrialYang-Si Li, Qitao Yu, Qing Bu, et al.
Pageof 33

Showing results (301-310 of 321) with videos related to

Sort By:
Pageof 33
Frontiers in Immunology|October 20, 2022
PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinomaYu-Min Zhong, Kai Yin, Yu Chen, et al.
Signal Transduction and Targeted Therapy|December 6, 2023
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II studySi-Yang Liu, Song Dong, Xue-Ning Yang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2017
Detection of Driver and Resistance Mutations in Leptomeningeal Metastases of NSCLC by Next-Generation Sequencing of Cerebrospinal Fluid Circulating Tumor CellsBen-Yuan Jiang, Yang-Si Li, Wei-Bang Guo, et al.
Journal of Translational Medicine|April 2, 2024
Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancerWei-Chi Luo, Shi-Qi Mei, Zi-Jian Huang, et al.
Journal of Hematology & Oncology|April 17, 2020
Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter studyChang Lu, Xiao-Rong Dong, Jun Zhao, et al.
Cancer Discovery|May 11, 2022
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung CancerJia-Tao Zhang, Si-Yang Liu, Wei Gao, et al.
Lung Cancer (Amsterdam, Netherlands)|November 28, 2017
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancerHai-Yan Tu, E-E Ke, Jin-Ji Yang, et al.
Lung Cancer (Amsterdam, Netherlands)|January 30, 2022
Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancerJianhua Chang, Yi-Long Wu, Shun Lu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 19, 2023
Allelic Context of EGFR C797X-Mutant Lung Cancer Defines Four Subtypes With Heterogeneous Genomic Landscape and Distinct Clinical OutcomesChang Lu, Xue-Wu Wei, Zhen Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 10, 2025
First-Line Camrelizumab Versus Placebo Plus Chemotherapy With or Without Radiotherapy for Brain Metastases in NSCLC: The CTONG 2003 Randomized Placebo-Controlled TrialYang-Si Li, Qitao Yu, Qing Bu, et al.
Pageof 33